# Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07025850/  
OnCo record `nct07025850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of tislelizumab in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07025850 by Fudan University, with a registry enrolment figure of 20 participants, started 2025-08-01 and due to reach its primary completion in 2027-01-01. Interventions recorded: Digoxin; Fuquinitinib; Tislelizumab. Conditions listed: Colorectal Carcinoma. Primary outcome: objective response rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07025850
- Phase: 1/2
- Setting: Phase II Clinical Study of Digoxin Combined With Fruquintinib and Tislelizumab in Patients With Advanced Primary Colorectal Cancer Who Failed Standard Therapy
- Sponsor: Fudan University
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07025850: https://clinicaltrials.gov/study/NCT07025850

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07025850.json